Erlotinib

Recent clinical results and ongoing studies in non-small cell lung cancer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib has shown to provide clinical benefit to patients with non - small cell lung cancer (NSCLC) after failure of front-line chemotherapy in a double-blind placebo-controlled clinical trial. More importantly, because of its unique mechanism of action, erlotinib seems to provide higher clinical benefit to specific subgroups of patients. The continued development of erlotinib in NSCLC is focused on the following areas: (a) validating clinical and molecular markers of clinical benefit in front-line therapy, (b) developing therapies for acquired and naturally resistant tumors, (c) revisiting combinations with chemotherapy, (d) developing combinations with antiangiogenesis agents, and (e) understanding the biological significance of the skin toxicity and developing rational approaches for its treatment. Clinical studies addressing these five areas are ongoing and are briefly described in this review.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume13
Issue number15
DOIs
StatePublished - Aug 1 2007

Fingerprint

Non-Small Cell Lung Carcinoma
Controlled Clinical Trials
Combination Drug Therapy
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Therapeutics
Biomarkers
Placebos
Drug Therapy
Skin
Erlotinib Hydrochloride
Neoplasms
Clinical Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Erlotinib : Recent clinical results and ongoing studies in non-small cell lung cancer. / Perez-Soler, Roman.

In: Clinical Cancer Research, Vol. 13, No. 15, 01.08.2007.

Research output: Contribution to journalArticle

@article{bef10ad9038c4348a1c620d267cd0b2b,
title = "Erlotinib: Recent clinical results and ongoing studies in non-small cell lung cancer",
abstract = "The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib has shown to provide clinical benefit to patients with non - small cell lung cancer (NSCLC) after failure of front-line chemotherapy in a double-blind placebo-controlled clinical trial. More importantly, because of its unique mechanism of action, erlotinib seems to provide higher clinical benefit to specific subgroups of patients. The continued development of erlotinib in NSCLC is focused on the following areas: (a) validating clinical and molecular markers of clinical benefit in front-line therapy, (b) developing therapies for acquired and naturally resistant tumors, (c) revisiting combinations with chemotherapy, (d) developing combinations with antiangiogenesis agents, and (e) understanding the biological significance of the skin toxicity and developing rational approaches for its treatment. Clinical studies addressing these five areas are ongoing and are briefly described in this review.",
author = "Roman Perez-Soler",
year = "2007",
month = "8",
day = "1",
doi = "10.1158/1078-0432.CCR-07-0541",
language = "English (US)",
volume = "13",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Erlotinib

T2 - Recent clinical results and ongoing studies in non-small cell lung cancer

AU - Perez-Soler, Roman

PY - 2007/8/1

Y1 - 2007/8/1

N2 - The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib has shown to provide clinical benefit to patients with non - small cell lung cancer (NSCLC) after failure of front-line chemotherapy in a double-blind placebo-controlled clinical trial. More importantly, because of its unique mechanism of action, erlotinib seems to provide higher clinical benefit to specific subgroups of patients. The continued development of erlotinib in NSCLC is focused on the following areas: (a) validating clinical and molecular markers of clinical benefit in front-line therapy, (b) developing therapies for acquired and naturally resistant tumors, (c) revisiting combinations with chemotherapy, (d) developing combinations with antiangiogenesis agents, and (e) understanding the biological significance of the skin toxicity and developing rational approaches for its treatment. Clinical studies addressing these five areas are ongoing and are briefly described in this review.

AB - The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib has shown to provide clinical benefit to patients with non - small cell lung cancer (NSCLC) after failure of front-line chemotherapy in a double-blind placebo-controlled clinical trial. More importantly, because of its unique mechanism of action, erlotinib seems to provide higher clinical benefit to specific subgroups of patients. The continued development of erlotinib in NSCLC is focused on the following areas: (a) validating clinical and molecular markers of clinical benefit in front-line therapy, (b) developing therapies for acquired and naturally resistant tumors, (c) revisiting combinations with chemotherapy, (d) developing combinations with antiangiogenesis agents, and (e) understanding the biological significance of the skin toxicity and developing rational approaches for its treatment. Clinical studies addressing these five areas are ongoing and are briefly described in this review.

UR - http://www.scopus.com/inward/record.url?scp=34547652646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547652646&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0541

DO - 10.1158/1078-0432.CCR-07-0541

M3 - Article

VL - 13

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -